Regional cell proliferation in microdissected human prostate specimens after heavy water labeling in vivo: Correlation with prostate epithelial cells isolated from seminal fluid

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3250-3260

  Hayes, Gregory M ^a   Simko, Jeff ^b   Holochwost, Daniel ^a   Kuchinsky, Kyle ^b   Busch, Robert ^a   Misell, Lisa ^a   Murphy, Elizabeth J ^a,c   Carroll, Peter ^c   Chan, June ^c   Shinohara, Katsuto ^c   Hellerstein, Marc K ^c,d  

^a KINEMED INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEUTERIUM OXIDE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; MICRODISSECTION; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SEMINAL PLASMA; SPERMATOCYTE;

ADULT; AGED; CELL PROLIFERATION; CELL SEPARATION; DEUTERIUM OXIDE; EPITHELIAL CELLS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SEMEN;

EID: 84862183974     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2988     Document Type: Article

References (31)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
2. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310- 9.
3. Tulinius H. Latent malignancies at autopsy: a little used source of information on cancer biology. IARC Sci Publ 1991:253 -61.
4. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010;304:2373-80.
5. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.
6. Laurila M, van der Kwast T, Bubendorf L, Bubendorf L, di Lollo S, Pihl CG, et al. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer 2010;46:3068-72.
7. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
8. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
9. Djavan B, Zlotta AR, Byttebier G, Shariat S, Omar M, Schulman CC, et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 1998;160:411-8; discussion 418 -9.
10. Carter HB, Morrell CH, Pearson JD, Brant LK, Plato CC, Metter EJ, et al. Estimation of prostatic growth using serial prostate-speci fi c antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323-8.
11. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, et al. Prostate-specifi c antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995;45:591-6.
12. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13:939-43. (Pubitemid 46340370)
13. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-5. (Pubitemid 46428401)
14. Williams GH, Stoeber K. The cell cycle and cancer. J Pathol 2012;226:352-64.
15. Lopergolo A, Zaffaroni N. Biomolecular markers of outcome prediction in prostate cancer. Cancer 2009;115:3058-67.
16. Busch R, Neese RA, Awada M, Hayes GM, Hellerstein MK. Measurement of cell proliferation by heavy water labeling. Nat Protoc 2007;2:3045- 57.
17. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-64. (Pubitemid 40322252)
18. Lindwall G, Hsieh EA, Misell LM, Chai CM, Turner SM, Hellerstein MK. Heavy water labeling of keratin as a non-invasive biomarker of skin turnover in vivo in rodents and humans. J Invest Dermatol 2006;126:841-8.
19. Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, et al. CD4+ T cell kinetics and activation in human immunode ficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002;185:315-23. (Pubitemid 34107244)
20. McCune JM, Hanley MB, Cesar D, Halvorsen R, Hoh R, Schmidt D, et al. Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest 2000;105:R1-8. (Pubitemid 30146516)
21. Chen JL, Peacock E, Samady W, Turner SM, Neese RA, Hellerstein MK, et al. Physiologic and pharmacologic factors in fluencing glyceroneogenic contribution to triacylglyceride glycerol measured by mass isotopomer distribution analysis. J Biol Chem 2005;280:25396-402. (Pubitemid 40962243)
22. Shankaran M, King C, Lee J, Busch R, Wolff M, Hellerstein MK. Discovery of novel hippocampal neurogenic agents by using an in vivo stable isotope labeling technique. J Pharmacol Exp Ther 2006;319:1172-81.
23. Neese RA, Misell LM, Turner S, Chu A, Kim J, Cesar D, et al. Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci U S A 2002;99:15345-50. (Pubitemid 35403937)
24. Strawford A, Antelo F, Christiansen M, Hellerstein MK. Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with 2H2O. Am J Physiol Endocrinol Metab 2004;286:E577-88. (Pubitemid 38374955)
25. Macallan DC, Fullerton CA, Neese RA, Haddock K, Park SS, Hellerstein MK. Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose: studies in vitro, in animals, and in humans. Proc Natl Acad Sci U S A 1998;95:708-13. (Pubitemid 28083808)
26. Suh CI, Shanafelt T, May DJ, Shroyer KR, Bobak JB, Crawford ED, et al. Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol Cell Probes 2000;14:211-7.
27. Barren RJ III, Holmes EH, Boynton AL, Gregorakis A, Elgamal AA, Cobb OE, et al. Method for identifying prostate cells in semen using flow cytometry. Prostate 1998;36:181-8. (Pubitemid 28341130)
28. Stattin P, Damber JE, Karlberg L, Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fi xed tissues is a predictive factor for survival in prostate cancer. J Urol 1997;157:219- 22.
29. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009;100:888-93.
30. Jones PJ, Leatherdale ST. Stable isotopes in clinical research: safety reaffirmed. Clin Sci (Lond) 1991;80:277-80.
31. Hayes G, principal investigator; KineMed. Sponsor. A CLL Research Consortium (CRC) phase II study of kinetic biomarker for chronic lymphocytic leukemia (CLL) prognosis. ClinicalTrials.gov Identifier: NCT00481858. NCI #5R44CA097686-05. 2011. Available from: http://www.healthetreatment.com/ clinical-trial/NCT00481858/.